Plasma concentration of high sensitive C-reactive protein (hsCRP) is used as a marker for inflammatory states and is directly correlated with the risk for coronary heart disease. Evidence concerning the role of inflammation in atheroma formation has been derived from several models of atherosclerosis. Inflammation should exert its adverse vascular effects by structural changes in the artery wall and consequently alterations in arterial elasticity, which could be detected already in asymptomatic early vascular disease. We hypothesized that CRP is related to large artery elasticity, but not to small artery elasticity in early vascular disease. Therefore, we examined the association between arterial stiffness of large and small arteries and inflammation in an asymptomatic population referred for primary prevention cardiovascular screening. Studies were performed in 391 subjects (age 21-82 years; 254 men, 137 women) who underwent screening at the Cardiovascular Disease Prevention Center. Large artery (C1) and small artery (C2) elasticity indices were obtained by the CVProfiler 2000 (HDI, Eagan, MN, USA). After overnight fasting, venous samples were taken for measurement of hsCRP, lipids, glucose. There was a significant inverse correlation between hsCRP (0.2970.40 mg/dl) and C1 (16.775.8 ml/mmHg), r ¼ À0.133, P ¼ 0.01; there was no significant correlation between hsCRP and C2 (6.673.2 ml/mmHg). C2, but not hsCRP, was inversely correlated with age, abnormal lipids and glucose, whereas C1, but not hsCRP, was inversely correlated with age and systolic blood pressure (SBP). In multiple regression analysis, the relationship between hsCRP and C1 was not affected by age, body mass index, SBP, serum glucose or lipids. In conclusion, these findings support the hypothesis that hsCRP, a marker for acute and low-grade inflammation, is associated with large artery but not with small artery elasticity in asymptomatic individuals undergoing primary prevention cardiovascular screening.
Introduction
The detection of preclinical disease of the artery wall may improve our ability to predict subsequent risk of atherosclerotic cardiovascular events and lead to optimal strategies to prevent progressive disease. New predictors are needed to improve the accuracy of risk stratification. Increased levels of biochemical markers of endothelial function, P-selectin, E-selectin, soluble intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and thrombomodulin have been found in patients with atherosclerosis and dyslipidaemia. [1] [2] [3] Recent studies provide evidence that inflammation plays a role in the pathogenesis of cardiovascular disease by contributing to the initiation and progression of atherosclerosis. [4] [5] [6] High sensitive C-reactive protein (hsCRP), a systemic marker for inflammation, has been shown to be directly related to the risk for cardiovascular disease in both cross-sectional and prospective studies, [7] [8] [9] [10] although the magnitude of the association is still controversial. 11 If inflammation is a marker for atherosclerotic events the relationship should be expressed through an inflammatory process in the wall of the conduit arteries that might exhibit cellular infiltration and thickening as a precursor to plaque formation. Such arterial wall structural changes would be expected to increase arterial stiffness or reduce arterial compliance.
Flow-mediated forearm vasodilation is a wellaccepted method to study endothelial function noninvasively. 12 The status of the endothelial function may modify the association between risk factors and atherosclerosis. However, flow-mediated vasodilation may be much more stressful for the subject or patient in contrast to pulse contour analysis of the arterial waveform registered at the radial artery. Pulse contour analysis allows separate assessment of the elasticity of the large conduit arteries, which predominantly influence the exponential decay of diastolic pressure, and the small artery elasticity, which influences the oscillations or reflections recorded during diastole. 13 Several studies have shown that arterial stiffness is an important predictor of cardiovascular morbidity and mortality in the general population and in specific populations. 14, 15 Indeed, if arterial wall inflammation leads to arterial stiffness, then a change in the pressure/volume relationship of the conduit arteries might be a more specific marker for vascular disease than nonspecific markers for inflammation. 16, 17 We hypothesized that hsCRP, as marker for inflammation, would be associated with large artery elasticity but not with small artery elasticity in asymptomatic individuals. Beyond this hypothesis we wanted to study the relationship of hsCRP and arterial elasticity to other contributors to atherosclerotic risk in this particular group.
Materials and methods

Subjects
Studies were performed in the first consecutive 391 subjects (age 21-82 years; 254 men and 137 women) who underwent screening at the Rasmussen Center for Cardiovascular Disease Prevention between 2000 and 2002. Table 1 summarizes the baseline demographics and the clinical characteristics of the study population. The Institutional Review Board at the University of Minnesota approved the protocol and an informed consent was obtained from all the patients. Venous blood samples were obtained after overnight fast. A full history was obtained and patients underwent a physical examination, with emphasis on the cardiovascular system.
Measurements of large and small artery elasticity
Radial arterial pulse waves were recorded noninvasively in the supine position with a piezoelectric sensor (Hypertension Diagnostics Inc, Eagan, MN, USA). The waveform was calibrated by the oscillometric method with a cuff on the opposite arm and a calibration system internal to the device. Waveforms were recorded for 30 s and the diastolic portion digitized at 200 samples per second. Waveforms were analysed using a curve fitting algorithm and a third-order equation. These waveforms were applied to a modified Windkessel model for calculation of large artery elasticity (C1) and small artery elasticity (C2) indices as previously described. 13 
Blood testing
Serum was obtained after an overnight fast and an hsCRP assay was performed by means of particleenhanced immunonephelometry using a Dade Behring BN100 analyzer (Dade Behring N High Sensitivity CRP Reagent; Dade Behring, Duluth, GA, USA). The detection limit of the assay is 0.018 mg/dl. Coefficients of variation were between 2.3% and 4.4% for intra-assay measurements and 2.1% and 5.7% for interassay measurements.
Total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides and glucose were also determined.
Statistical analysis
All data are expressed as mean7standard deviation (SD), unless stated otherwise. Logarithmically transformed hsCRP and triglycerides were used for statistical analyses. The distribution of other variables was satisfactory for parametric tests. Unpaired Student's t-test and Mann-Whitney tests were used to compare baseline demographics and hsCRP levels. Spearman's correlation coefficients were used to quantify the relationship between hsCRP and other variables. Univariate and multivariate regression analyses were performed with hsCRP as the dependent variable. Only variables that were significantly associated with hsCRP in univariate regression analyses were used in multiple regression analyses. Significance was considered at the P-level less than 0.05. There was a significant gender difference in hsCRP levels (men, 0.2470.36 g/dl; women, 0.3770.45 mg/dl, P ¼ 0.001).
A significant inverse correlation was noted between log-hsCRP and C1 (r ¼ À0.133, P ¼ 0.01) (Tables 2 and 3), whereas there was no significant correlation between log-hsCRP and C2 (r ¼ À0.039) ( Table 4 ). C1 was inversely correlated with age, SBP, pulse pressure (pp) and lipid levels as well as with hsCRP (Table 3) . Risk markers for endothelial dysfunction and atherosclerosis (ageing, increased cholesterol, low HDL, fasting blood sugar, SBP) were correlated inversely with C2 (Table 4 ), but not with hsCRP (Table 2) .
In univariate regression analysis with log-hsCRP as the dependent variable, only body mass index (BMI), C1, total cholesterol and log-triglycerides were significantly associated with hsCRP but not age, SBP, DBP, PP, C2, LDL-cholesterol, HDL-cholesterol or serum-glucose. In multivariate regression analysis only C1 (P ¼ 0.004) and BMI (P ¼ 0.0001) but not total cholesterol or log-triglycerides remained significantly associated with hsCRP.
Discussion
The evidence that CRP levels, a plasma marker for inflammation, are correlated with the risk for atherosclerotic morbid events lends support to the concept that inflammation is a contributor to the atherosclerotic process. [4] [5] [6] 10, 11 The biological marker that should link CRP and atherosclerosis would be a measure of arterial wall structural change. Thus our finding that CRP levels are correlated with reduced elasticity or increased stiffness of the large conduit arteries is consistent with this hypothesis.
The large artery structural changes that characterize the atherosclerotic process are dependent for their development on endothelial dysfunction, which permits cell adhesion and wall infiltration. Inflammation facilitates that infiltrative process and thus would be expected to be associated with the severity of the structural change. 18, 19 Nonetheless, inflammation without endothelial dysfunction might not be associated with atherosclerosis, and endothelial dysfunction without inflammation might have a more benign course. Thus the correlations among these markers -inflammation as identified by CRP, endothelial dysfunction as identified by reduced small artery elasticity, 20 and structural changes in the conduit arteries as identified by large artery stiffness -would be expected to be modest. The correlations identified in this population are consistent with this construct. Despite the correlation between large artery stiffness and CRP, other factors independently influence these markers. [21] [22] [23] [24] New biomarkers are closely linked to the pathological mechanisms that underly the progression of atherosclerotic disease which ultimately precipitate acute clinical events. Current concepts of atherogenesis include involvement of the immune system and chronic inflammation. 4, 5 The upregulation of the expression of adhesion molecules in the vascular endothelium is the initiating event in this process and allows leucocyte and monocyte adhesions to the endothelial cell surface. After adhesions, upregulation of endothelial adhesions induces leucocyte and monocyte penetration into the subendothelial environment, where tumour-necrosis factor (TNF)-a, interleukin (IL-6) and other cytokines are released, resulting in recruitment of additional circulating cells. The membrane-spanning protein CD 40 is also upregulated in activated endothelial cells and leucocytes and, after engagement with its natural ligand CD40L, which is expressed in monocytes and T lymphocytes, amplifies atherogenesis by further promoting cytokine release and adhesion of circulating cells to the endothelium. 25, 26 In a similar way, hsCRP, which is released by the liver in response to IL-6, acts both as a marker and a contributor to the vascular inflammation. A key determinant of inflammation is the increased generation of reactive oxygen species. 27 Although in vitro methods allow investigations of these inflammatory processes, endothelial proinflammatory activation is difficult to evaluate in vivo. Thus, a number of molecules are currently available to assess endothelial function and the ongoing inflammatory process in the vascular wall. 28 Ageing produces a progressive decline in both large artery and small artery elasticity consistent with the well-recognized relationship between age and the risk for cardiovascular events. 29 In contrast, CRP did not increase with age and did not correlate with small artery elasticity, a marker for endothelial dysfunction, or with the biochemical markers for atherosclerosis risk. Thus CRP appears to serve as an accelerator of atherosclerosis in individuals who exhibit early disease, not as an initiator of the process (Table 5) .
These data thus provide an attractive hypothesis that is consistent with previous experimental and clinical data. Endothelial dysfunction, as identified by a reduced C2, is an early marker for the risk of atherosclerosis, and this endothelial dysfunction may be induced or aggravated by glucose, LDL or reduced HDL. In the presence of inflammation the process of atherosclerosis is accelerated, thereby leading to reduced large artery elasticity and an elevated SBP and PP (Figure 1) . Therefore, hsCRP, C1 and C2 may provide some insight into the atherosclerotic disease risk or presence: C2 as the earliest marker for endothelial dysfunction, CRP as a facilitator of conduit artery structural change if the endothelium is dysfunctional, and C1 as a marker for the structural change in the conduit arteries. If this hypothesis is correct, then the best marker for progressive artherosclerotic disease could be a combination of all three. Documentation of the sensitivity of such a composite assessment must await the collection of longerterm follow-up data. Figure 1 Model of the possible role of hsCRP on large and small arteries in the pathogenesis of atherosclerosis.
